|
sars-cov-2 |
11 |
|
autoimmune disorders |
10 |
|
covid-19 vaccine |
10 |
|
spondyloarthritis |
10 |
|
lupus nephritis |
8 |
|
model |
8 |
|
prediction |
8 |
|
risk assessment |
8 |
|
systemic lupus erythematosus |
8 |
|
inflammation |
7 |
|
stroke |
7 |
|
ankylosing spondylitis |
6 |
|
ankylosing spondylitis disease activity index |
6 |
|
axial spondyloarthritis |
6 |
|
cardiovascular event |
6 |
|
cerebrovascular event |
6 |
|
diffusion-weighted imaging |
6 |
|
mri |
6 |
|
myocardial infarction |
6 |
|
allergy |
5 |
|
bdmards |
5 |
|
cardiovascular safety of biologics |
5 |
|
drug |
5 |
|
hypersensitivity |
5 |
|
incidence |
5 |
|
infliximab |
5 |
|
jak inhibitors |
5 |
|
prevalence |
5 |
|
real-world observational study |
5 |
|
rheumatoid arthritis |
5 |
|
rheumatology |
5 |
|
antirheumatic agents |
4 |
|
asas criteria |
4 |
|
cervical cancer |
4 |
|
corner inflammatory lesion |
4 |
|
diagnosis |
4 |
|
epidemiology |
4 |
|
fungal |
4 |
|
modified new york criteria |
4 |
|
mortality |
4 |
|
pneumonia |
4 |
|
prophylaxis |
4 |
|
risk |
4 |
|
uveitis |
4 |
|
apparent diffusion coefficient |
3 |
|
bath ankylosing spondylitis metrology index |
3 |
|
biologics |
3 |
|
community-acquired pneumonia |
3 |
|
dermatomyositis |
3 |
|
disease modifying anti-rheumatic drugs |
3 |
|
glucocorticoid |
3 |
|
interstitial lung disease |
3 |
|
magnetic resonance imaging |
3 |
|
mda5 |
3 |
|
pneumomediastinum |
3 |
|
short tau inversion recovery sequence |
3 |
|
smoking |
3 |
|
spondyloarthritis research consortium of canada mri |
3 |
|
steroid |
3 |
|
tuberculosis |
3 |
|
artificial intelligence |
2 |
|
deep learning |
2 |
|
infections |
2 |
|
losing spondylitis spine score |
2 |
|
modified stoke anky |
2 |
|
psoriasis |
2 |
|
sacroiliitis |
2 |
|
sparcc scoring system |
2 |
|
spine |
2 |
|
steroids |
2 |
|
stir-mri |
2 |
|
urinary tract infection |
2 |
|
covid-19 |
1 |
|
outcome |
1 |
|
pulmonary embolism |
1 |
|
thromboembolic disease |
1 |
